武田药品2024年第三季度GAAP每股收益为15.01日元，同比下降67.38日元，销售额为1.144万亿日元，超出预期1.139万亿日元

财报速递2025-01-30

武田药品 (NYSE:TAK) 报告季度每股收益为15.01日元。这较去年同期的每股收益67.38日元下降了77.72%。公司报告季度销售额为1.144万亿日元，超出分析师一致预期的1.139万亿日元，超出0.42%。这较去年同期的1.111万亿日元销售额增长了2.97%。

以上内容来自Benzinga Earnings专栏，原文如下：

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of ¥15.01 per share. This is a 77.72 percent decrease over earnings of ¥67.38 per share from the same period last year. The company reported quarterly sales of ¥1.144 trillion which beat the analyst consensus estimate of ¥1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of ¥1.111 trillion the same period last year.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1118495484?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-30 14:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118495484","market":"us","top_or_hot":-1,"title":"武田药品2024年第三季度GAAP每股收益为15.01日元，同比下降67.38日元，销售额为1.144万亿日元，超出预期1.139万亿日元","media":"财报速递","content":"武田药品 (NYSE:TAK) 报告季度每股收益为15.01日元。这较去年同期的每股收益67.38日元下降了77.72%。公司报告季度销售额为1.144万亿日元，超出分析师一致预期的1.139万亿日元，超出0.42%。这较去年同期的1.111万亿日元销售额增长了2.97%。<br><br>以上内容来自Benzinga Earnings专栏，原文如下：<br><html><body><p>Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of ¥15.01 per share. This is a 77.72 percent decrease over earnings of ¥67.38 per share from the same period last year. The company reported quarterly sales of ¥1.144 trillion which beat the analyst consensus estimate of ¥1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of ¥1.111 trillion the same period last year.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>武田药品2024年第三季度GAAP每股收益为15.01日元，同比下降67.38日元，销售额为1.144万亿日元，超出预期1.139万亿日元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n武田药品2024年第三季度GAAP每股收益为15.01日元，同比下降67.38日元，销售额为1.144万亿日元，超出预期1.139万亿日元\n</h2>\n\n<h4 class=\"meta\">\n\n2025-01-30 14:56 北京时间&nbsp;&nbsp;&nbsp;<strong>财报速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>武田药品 (NYSE:TAK) 报告季度每股收益为15.01日元。这较去年同期的每股收益67.38日元下降了77.72%。公司报告季度销售额为1.144万亿日元，超出分析师一致预期的1.139万亿日元，超出0.42%。这较去年同期的1.111万亿日元销售额增长了2.97%。以上内容来自Benzinga Earnings专栏，原文如下：Takeda Pharmaceutical (NYSE:TAK)...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"","article_id":"1118495484","we_media_id":"1048278264","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118495484","pubTimestamp":1738220174,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"财报速递","introduction":"每日财报追踪","home_visible":1,"id":"1048278264","head_image":"https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f"},"summary":"武田药品  报告季度每股收益为15.01日元。这较去年同期的每股收益67.38日元下降了77.72%。公司报告季度销售额为1.144万亿日元，超出分析师一致预期的1.139万亿日元，超出0.42%。以上内容来自Benzinga Earnings专栏，原文如下：Takeda Pharmaceutical  reported quarterly earnings of 15.01 per share. This is a 77.72 percent decrease over earnings of 67.38 per share from the same period last year. The company reported quarterly sales of 1.144 trillion which beat the analyst consensus estimate of 1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of 1.111 trillion the same","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"TAK":"武田制药"},"translate_title":"Takeda Pharmaceuticals Q3 2024 GAAP EPS of JPY 15.01, down JPY 67.38 YY, sales of JPY 1.144 trillion beat expectations of JPY 1.139 trillion","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":0.9},"content_text":"武田药品 (NYSE:TAK) 报告季度每股收益为15.01日元。这较去年同期的每股收益67.38日元下降了77.72%。公司报告季度销售额为1.144万亿日元，超出分析师一致预期的1.139万亿日元，超出0.42%。这较去年同期的1.111万亿日元销售额增长了2.97%。以上内容来自Benzinga Earnings专栏，原文如下：Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of ¥15.01 per share. This is a 77.72 percent decrease over earnings of ¥67.38 per share from the same period last year. The company reported quarterly sales of ¥1.144 trillion which beat the analyst consensus estimate of ¥1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of ¥1.111 trillion the same period last year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118495484","isCrawlerRequest":true}